Thanks for the insights (Mason and Davisite also)

First 141 Last

Share
Profile

Follow
DrSanchez

378 Posts.

89

18/07/24

11:59

Post #: 74810165
Share

Originally posted by KingBuzzo: ↑

I'm sure there are currently huge amounts of thought being put into these kind of questions. My thoughts are as follows:

1) As Dr T. says, above, it's all about safety and cardioprotection. If they know the MoA of cardioprotection, we can assume they have a good idea of the dosing required to achieve it, and it's likely lower and/or shorter in duration than what is required for optimal anti-cancer activity. Since this is the first time that dox and bis have been dosed together, the safest bet is to start small. Imagine if Race went hard early with high/long/frequent dosing of bisantrene in this trial and failed to show either cardioprotection or anti-cancer activity due to some unforeseen toxicity.

2) There may be more sensitive measures of anti-cancer activity available to Race to monitor than just SD/PR/CR, which for example could potentially demonstrate a small/temporary reduction in cancer burden during the bisantrene dosing which reverses as bis is eliminated from the patient's system.

3) As the trial progresses and safety is demonstrated, perhaps that will allow increasing bisantrene dosing in both strength and frequency as part of dose escalation. We have yet to see the trial design.

4) The investigator-led AML trial may hopefully end up running more-or-less concurrently, and one would assume this trial will be dosing for maximum anti-cancer effectiveness. I'm not sure if this trial is also open label as there has been very little information regarding it forthcoming so far, but if so we could potentially be receiving preliminary data for both anti-cancer and cardioprotection in a similar time-frame.

Expand

Thanks for the insights (Mason and Davisite also)

RAC Price at posting: $1.80 Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

NRX

Noronex joins forces with South32 to look for copper in Namibia

Talking Australia's very competitive property landscape: Realty Talks

AI stocks: What to expect in 2024-25

EVN

Evolution shares up 3% on quarterly results for June showing rise in gold production

FMG

Andrew Forrest was seemingly possessed by the spirit of hydrogen – now he's cut 700 jobs and canned FFI

There are more pages in this discussion • 6 more messages in this thread...

First 141 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.86		Change -0.015(0.80%)		Mkt cap ! $316.8M

Open	High	Low	Value	Volume
$1.88	$1.88	$1.79	$163.0K	89.00K

Buyers (Bids)

No.	Vol.	Price($)
2	34299	$1.84

Sellers (Offers)

Price($)	Vol.	No.
$1.86	3635	1

View Market Depth

No.	Vol.	Price($)
2	34299	1.840
1	3000	1.810
1	1106	1.800
1	1231	1.790
1	11000	1.780

Price($)	Vol.	No.
1.860	3635	1
1.875	198	1
1.895	3000	1
1.900	33	1
1.940	5148	2

Last trade - 16.10pm 18/07/2024 (20 minute delay)

RAC (ASX) Chart

Thanks for the insights (Mason and Davisite also)

Noronex joins forces with South32 to look for copper in Namibia

Talking Australia's very competitive property landscape: Realty Talks

AI stocks: What to expect in 2024-25

Evolution shares up 3% on quarterly results for June showing rise in gold production

Andrew Forrest was seemingly possessed by the spirit of hydrogen – now he's cut 700 jobs and canned FFI

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thanks for the insights (Mason and Davisite also)

Top Stories

Noronex joins forces with South32 to look for copper in Namibia

Talking Australia's very competitive property landscape: Realty Talks

AI stocks: What to expect in 2024-25

Evolution shares up 3% on quarterly results for June showing rise in gold production

Andrew Forrest was seemingly possessed by the spirit of hydrogen – now he's cut 700 jobs and canned FFI

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News